Novartis has launched Diovan 3mg/ml Oral Solution for the treatment of hypertension in children and adolescents 6 to 18 years of age.

It is not recommended to switch between Diovan tablets and Diovan oral solution unless clinically required as there is insufficient information to guide an appropriate dose on switching between the two formulations. Indirect comparisons suggest that, the oral bioavailability of valsartan with the solution is approximately 2-fold higher than the tablets. If switching is necessary then refer to dosage conversion table in SPC.